CDC and mRNA COVID-19 Vaccine Induced Myocarditis/Pericarditis Myocarditis after Covid-19 Vaccination in a Large Health Care Careers. From an analysis done on just 26 medical chart-confirmed cases of myocarditis in people ages 12 to 39, the CDC scientists estimated a rate of 12.6 cases per million second doses. Only about 1 out of 100 cases of heart inflammation linked with COVID-19 vaccines is life-threatening.5 An analysis of 627 cases of vaccine-linked myocarditis worldwide showed that 626 fully recovered and one fatality.7. Serious side effects are very uncommon. Myocarditis is a rare complication of COVID-19 vaccination. Among all participants aged 16 to 24, myocarditis rates were 18.8 and 4.4 per 100,000 person-years for males and females, respectively. Myocarditis related to COVID-19 vaccines seems to be caused by the bodys immune response to vaccination.
Young Men's Myocarditis Risk 5 Times Higher With Moderna vs Pfizer Vax No alternatives to mRNA COVID-19 vaccines for adolescents will be available for the foreseeable future, and vaccination of adolescents offers protection against COVID-19 that can be important for returning to educational, social, and extracurricular activities. A., Christakis, D. A., Cowell, L. G., Draper, C., Ghildayal, N., Harris, A. M., Kappelman, M. D., Ko, J. Y., Mayer, K. H., Nagavedu, K., Oster, M. E., Paranjape, A., Puro, J., Ritchey, M. D., Gundlapalli, A. V. (2022). (Jolygon/iStock via Getty Images) The risk of developing myocarditis - an inflammation of the heart muscle - following a booster dose of the Pfizer COVID-19 vaccine is low, according to new research from Israel. CDC and its partners are actively monitoring reports of myocarditis and pericarditis after COVID-19 vaccination.
Myocarditis risk higher after Covid infection than Pfizer or Moderna Between 2001 and 2020, the Institute has funded 139 myocarditis studies at a cost of $43.6 million. We spoke with Fleg about the risk of myocarditis linked with COVID-19 illness and with vaccines. %PDF-1.7
FLEG: The NHLBI has a strong history of conducting and funding research on myocarditis. For the BNT162b2 vaccine, there were 114246837 first vaccination doses and 95532396 second vaccination doses; and for the mRNA-1273 vaccine, there were 78158611 and 66163001, respectively.
Information for healthcare professionals on myocarditis and Information regarding the risk for myocarditis with mRNA COVID-19 vaccines should be disseminated to providers to share with vaccine recipients. You can review and change the way we collect information below. 2023 Mar 2:1-14. doi: 10.1007/s13181-023-00931-9. Myocarditis typically causes shortness of breath and chest pain.
How Often Do Covid Vaccines Cause Heart Problems in Kids? Potential cases of postvaccine myocarditis were identified based on reports . MMWR. Both mRNA vaccines were authorized and recommended as a 2-dose schedule, with second doses administered 21 days (Pfizer-BioNTech) or 28 days (Moderna) after the first dose. Reported cases of the rare heart . You can review and change the way we collect information below. Dr Edwards reported receiving grants from the National Institutes of Health; receiving personal fees from BioNet, IBM, X-4 Pharma, Seqirus, Roche, Pfizer, Merck, Moderna, and Sanofi; and receiving compensation for being the associate editor of Clinical Infectious Diseases. That means the vaccines protect heart health.
Researchers compare the risk of myocarditis between Pfizer and Moderna References to non-CDC sites on the Internet are
Your health care provider can provide more information thats specific to your situation. Its important to remember that any vaccine can cause side effects. <>
Your chance of getting myocarditis after getting a COVID-19 vaccine is less than the chance of being struck by lightning during your lifetime. Myocarditis is rare, but it occurs more often following SARS-CoV-2 infection than after receiving an mRNA COVID-19 vaccine for people of all ages.10, We know that boys and men between the ages of 16 and 29 have a higher risk of COVID-19vaccine-related myocarditis. The risks and outcomes of myocarditis after COVID-19 vaccination are unclear. These are normal signs that your body is making protective antibodies. Cordero, A., Cazorla, D., Escribano, D., Quintanilla, M. A., Lpez-Ayala, J. M., Berbel, P. P., & Bertomeu-Gonzlez, V. (2022). and/or the original MMWR paper copy for printable versions of official text, figures, and tables. All information these cookies collect is aggregated and therefore anonymous. To assess the benefit-risk balance of mRNA vaccines in adolescents and young adults, ACIP reviewed an individual-level assessment that compared the benefits (i.e., COVID-19 infections and severe disease prevented) to the risks (number of cases of myocarditis) of vaccination, using methods similar to those described previously. Specifically, the benefits per million second doses administered (i.e., the benefits of being fully vaccinated in accordance with the FDA EUA) were assessed, including 1) COVID-19 cases prevented based on rates the week of May 29, 2021; 2) COVID-19 hospitalizations prevented based on rates the week of May 22, 2021; and 3) COVID-19 intensive care unit (ICU) admissions and deaths prevented based on the proportion of hospitalized patients who were admitted to the ICU or died. Epidemiology of Myocarditis and Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in Ontario, Canada. On June 23, 2021, the Advisory Committee on Immunization Practices concluded that the benefits of COVID-19 vaccination to individual persons and at the population level clearly outweighed the risks of myocarditis after vaccination. URL addresses listed in MMWR were current as of
2 0 obj
Age was not reported for 32 patients, and sex was not reported for 14 patients. Gurdasani, D., Bhatt, S., Costello, A., Denaxas, S., Flaxman, S., Greenhalgh, T., Griffin, S., Hyde, Z., Katzourakis, A., McKee, M., Michie, S., Ratmann, O., Reicher, S., Scally, G., Tomlinson, C., Yates, C., Ziauddeen, H., & Pagel, C. (2021). Users are referred to the electronic PDF version (https://www.cdc.gov/mmwr)
Abbreviations: ICU=intensive care unit; VAERS = Vaccine Adverse Event Reporting System. Before Observed cases of myocarditis reported to VAERS after Moderna dose 2, 7-day risk period (N=216)* Age group, years Females Males Cases of myopericarditis, expected Cases of . The CONNECTS-Collaborative Cohort of Cohorts for COVID-19 Research (CONNECTS-C4R) trial is enrolling 50,000 people to determine factors that may predict disease severity and long-term side effects of COVID-19. (2022). The clinical presentation and severity of myocarditis vary among patients. CDC is not responsible for the content
Acute clinical courses were generally mild; among 304 hospitalized patients with known clinical outcomes, 95% had been discharged at time of review, and none had died. To describe reports of myocarditis and the reporting rates after mRNA-based COVID-19 vaccination in the US. Since April, more than 1,000 cases of inflammation of the . Because of uncertainty in the accuracy of myocarditis reporting, given that reviews are ongoing, and some cases might not have been reported yet, myocarditis reporting rates are presented as a range of values, calculated as 10% of the observed reporting rates. If you need to go back and make any changes, you can always do so by going to our Privacy Policy page. Even though the studies were among the largest vaccine trials in history, they were not large enough to detect very rare complications like myocarditis that occur only a few times per million vaccinations. These cookies perform functions like remembering presentation options or choices and, in some cases, delivery of web content that based on self-identified area of interests. Myocarditis reporting rates were 40.6 cases per million second doses of mRNA COVID-19 vaccines administered to males aged 1229 years and 2.4 per million second doses administered to males aged 30 years; reporting rates among females in these age groups were 4.2 and 1.0 per million second doses, respectively. The rates of myocarditis were highest after the second vaccination dose in adolescent males aged 12 to 15 years (70.7 per million doses of the BNT162b2 vaccine), in adolescent males aged 16 to 17 years (105.9 per million doses of the BNT162b2 vaccine), and in young men aged 18 to 24 years (52.4 and 56.3 per million doses of the BNT162b2 vaccine and the mRNA-1273 vaccine, respectively). Myocarditisisinflammation of the heart muscle. Another study is enrolling 500 survivors of COVID-19 to monitor their hearts for long-term effects of COVID-19, using cardiac MRI and echocardiography scans. Diagnostic evaluation might reveal an elevated troponin level or abnormal findings on electrocardiogram, echocardiogram, or cardiac magnetic resonance imaging (Table 1). The benefits (prevention of COVID-19 disease and associated hospitalizations, ICU admissions, and deaths) outweighed the risks (expected myocarditis cases after vaccination) in all populations for which vaccination has been recommended. In December 2020, the Food and Drug Administration (FDA) issued Emergency Use Authorizations (EUAs) for the Pfizer-BioNTech COVID-19 (BNT162b2) vaccine and the Moderna COVID-19 (mRNA-1273) vaccine, and the Advisory Committee on Immunization Practices (ACIP) issued interim recommendations for their use in persons aged 16 years and 18 years, respectively. In May 2021, FDA expanded the EUA for the Pfizer-BioNTech COVID-19 vaccine to include adolescents aged 1215 years; ACIP recommends that all persons aged 12 years receive a COVID-19 vaccine. Mary Chamberland, Thomas Clark, Amanda Cohn, Frank DeStefano, Ruth Gallego, Alice Guh, Theresa Harrington, Fiona P. Havers, Lauri Hicks, Amelia Jazwa, Tara Johnson, Brian Kit, Paige Marquez, Sarah Mbaeyi, Elaine Miller, Hannah Rosenblum, Monica Parise, Kadam Patel, Pragati Prasad, David Shay, Jamila Shields, Christopher A. Taylor, Joshua Wong, CDC COVID-19 Response Team; Clinical Immunization Safety Assessment (CISA) Project; Vaccine Safety Datalink; Center for Biologics Evaluation and Research, Food and Drug Administration; Voting members of the Advisory Committee on Immunization Practices: Kevin A. Ault, University of Kansas Medical Center; Lynn Bahta, Minnesota Department of Health; Henry Bernstein, Zucker School of Medicine at Hofstra/Northwell Cohen Childrens Medical Center; Beth Bell, University of Washington, Seattle, Washington; Wilbur Chen, University of Maryland School of Medicine; Sharon E. Frey, Saint Louis University Medical School; Camille Kotton, Harvard Medical School; Sarah Long, Drexel University College of Medicine; Katherine A. Poehling, Wake Forest School of Medicine; Pablo J. Snchez, The Research Institute at Nationwide Childrens Hospital. Chary M, Barbuto AF, Izadmehr S, Tarsillo M, Fleischer E, Burns MM. Cases of myocarditis and pericarditis, although rare, have occurred more often in younger men (adolescents or young adults) and after the second dose, typically within a few days after . Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military. Buchan SA, Seo CY, Johnson C, Alley S, Kwong JC, Nasreen S, Calzavara A, Lu D, Harris TM, Yu K, Wilson SE. The study shows a low but significant rate of myocarditis among vaccine recipients, at less than 1 per 100,000 recipients. CDC has provided guidance regarding evaluation and management of myocarditis after mRNA COVID-19 vaccine (https://www.cdc.gov/vaccines/covid-19/clinical-considerations/myocarditis.html), as well as considerations for a second vaccine dose in persons who develop myocarditis after a first dose (https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html). An analysis of 51 patients with possible or confirmed myocarditis showed that 70% were male, and the average age was 56. Montgomery J, Ryan M, Engler R, Hoffman D, McClenathan B, Collins L, Loran D, Hrncir D, Herring K, Platzer M, Adams N, Sanou A, Cooper LT Jr. JAMA Cardiol. 2023 Feb 1;6(2):e2253845. Figure 1.. Cases of Myocarditis After mRNA-Based, Figure 1.. Cases of Myocarditis After mRNA-Based COVID-19 Vaccination by Age at Onset of Myocarditis, Figure 2.. Cases of Myocarditis After mRNA-Based, Figure 2.. Cases of Myocarditis After mRNA-Based COVID-19 Vaccination by Time From Vaccination to Symptom, MeSH On July 6, 2021, this report was posted online as an MMWR Early Release. JAMA Netw Open. Conflict of Interest Disclosures: Dr Creech reported receiving grants from the National Institutes of Health for the Moderna and Janssen clinical trials and receiving personal fees from Astellas and Horizon. Researchers are still investigating what triggers myocarditis after Covid vaccination.
Myocarditis rates were highest after the second vaccination dose in young males between 12 and 15 years of age (70.7 per million doses of the BNT162b2 vaccine), in adolescent males age 16 to 17 years (105.9 per million doses of the BNT162b2 vaccine), and in young men age 18 to 24 years (52.4 and 56.3 per million doses of the BNT162b2 vaccine . The vaccine product-specific EUA fact sheet should be provided to all vaccine recipients and their caregivers before vaccination with any authorized COVID-19 vaccine. 8600 Rockville Pike According to the TGA, the current overall estimated rates for the entire population of myocarditis for Pfizer and Moderna are similar - 1.4 cases per 100,000 Pfizer doses versus 1.8 cases per 100,000 Moderna doses. All information these cookies collect is aggregated and therefore anonymous. JAMA Netw Open. Pericarditisis inflammation of the outer lining of the heart. official website and that any information you provide is encrypted The ACIP recommendation for use of mRNA COVID-19 vaccines under an EUA is interim and will be updated as additional information becomes available. Males comprised 82% of the myocarditis cases for whom sex was reported. They help us to know which pages are the most and least popular and see how visitors move around the site. Moderna defended the use of its Covid vaccine, saying the protection it offers against severe disease, hospitalization and death outweighs the risk of myocarditis. For Moderna's vaccine, rates of myocarditis or pericarditis overall were 23 cases per million first doses and 62.5 cases per million second doses.
Myocarditis | American Heart Association The Vaccine Safety Datalink: a model for monitoring immunization safety. * This analysis evaluated direct benefits and harms, per million second doses of mRNA COVID-19 vaccine given in each age group, over 120 days. <>/Metadata 2557 0 R/ViewerPreferences 2558 0 R>>
To receive email updates about COVID-19, enter your email address: We take your privacy seriously. Posts making claims regarding the mortality rate of children diagnosed with COVID-19-linked myocarditis are viewable here, here. Vaccine 2015;33:4398405. government site. myocarditis and pericarditis and the mRNA COVID-19 vaccines, made by Moderna and Pfizer-BioNTech, in some vaccine recipients. They suggest the rates of myocarditis after the Moderna-NIAID vaccine may be two-and-a-half times higher.
COVID-19 subcommittee of the WHO Global Advisory Committee on Vaccine Approximately 96% of persons (784/813) were hospitalized and 87% (577/661) of these had resolution of presenting symptoms by hospital discharge. Information on how to submit a report to VAERS is available at https://vaers.hhs.gov/index.htmlexternal icon or 1-800-822-7967. 2023 Feb 5;11(2):362. doi: 10.3390/vaccines11020362. * These authors contributed equally to this work. **** https://gis.cdc.gov/grasp/COVIDNet/COVID19_5.html. Yes. Regarding health equity considerations, racial and ethnic minority groups have higher rates of COVID-19 and severe disease*****; potential changes in vaccine policy, or anything that would affect vaccination coverage for adolescents or young adults, might disproportionately affect those groups with the highest rates of poor COVID-19 outcomes. Seek medical care if you or your child have any of the specific or general symptoms of myocarditis or pericarditis especially if its within a week after COVID-19 vaccination. FLEG: Vaccination helps protect people from getting sick or severely ill with COVID-19 and helps protect those around them. 2022 Jul 13;378:e069445. However, COVID-19 illness is far more likely to cause myocarditis than are the vaccines. scientist on Monday, every million doses of the Pfizer vaccine administered to 16- and 17-year-old boys would be expected to cause 73 cases of the . A recent study classifying Long COVID into four types can help health care providers better target treatments for a patients specific symptoms. Side effects of COVID-19 vaccination are generally mild discomfort at the injection site, fatigue, and muscle aches and go away in a few days. One thing we don't know is the real rate of myocarditis with the original two-dose primary series of Pfizer and Moderna. Myocarditis typically occurs more commonly in males than in females, and incidence is highest among infants, adolescents, and young adults (1,2). Most of the suspected myocarditis cases in that study developed after the second dose and were among males between 12 and 39 years old. In cases of v-safe reports that include possible medically attended health events, CDCs v-safe call center follows up with the vaccine recipient to collect additional information for completion of a VAERS report. https://www.cdc.gov/vaccines/covid-19/info-by-product/janssen/risk-benefit-analysis.html. This term may be used for patients who meet criteria for both myocarditis and pericarditis. Moderna said the majority of the infections were mild. Case Description and Clinical Course a. . Baggs J, Gee J, Lewis E, et al. Because these studies are in their early phases, the results are not ready yet. Bookshelf The EUA fact sheets should be provided before vaccination; in addition, CDC has developed patient and provider education materials about the possibility of myocarditis and symptoms of concern, to ensure prompt recognition and management of myocarditis. The estimated incidence of myocarditis was 2 per 100,000 individuals, with the highest reported rate in males aged 16 to 29. Most had other health conditions, such as high blood pressure, diabetes, or obesity, that raised their risk for serious COVID-19 illness.4.
SARS-CoV-2 vaccination and myocarditis or myopericarditis - The BMJ As of June 11, 2021, approximately 296 million doses of mRNA COVID-19 vaccines had been administered in the United States, with 52 million administered to persons aged 1229 years; of these, 30 million were first and 22 million were second doses. Vaccination against COVID-19 provides clear public health benefits, but vaccination also carries potential risks.
Myocarditis With COVID-19 mRNA Vaccines | Circulation https://covid.cdc.gov/covid-data-tracker/#demographicsovertime. The y-axis range differs between panels A and B. Design, setting, and participants: The F.D.A. Abbreviations: AV = atrioventricular; cMRI=cardiac magnetic resonance imaging; ECG or EKG=electrocardiogram. Six awards are related to COVID-19related myocarditis.
Moderna says Covid vaccine has fewer breakthrough cases than Pfizer's Myocarditis rates from Vaccine Safety Datalink (VSD), based on electronic health records, were also evaluated. Myocarditis Occurs Earlier, Pericarditis Later Several reports to date have shown a higher-than-expected rate of myocarditis or pericarditis following SARS-CoV-2 vaccination, particularly with the mRNA-based vaccines from Pfizer/BioNTech and Moderna. 2021 Oct 1;6(10):1202-1206. doi: 10.1001/jamacardio.2021.2833.
Fact Check-What we know about myocarditis, COVID-19 infection, and Table 2. As of now, the FDA Fact Sheet for Moderna's shot says "Myocarditis and pericarditis have occurred . This analysis did not include the potential benefit of preventing post-COVID-19 conditions, such as prolonged symptoms and MIS-C (6,7). Based on ACIPs conclusion regarding the benefit-risk assessment on June 23, 2021, COVID-19 vaccination continues to be recommended for all persons aged 12 years under the FDAs EUA. doi: 10.1001/jamanetworkopen.2022.53845. Were currently supporting two large studies looking at long-term effects of COVID-19, including myocarditis and other heart conditions. There were 826 cases of myocarditis among those younger than 30 years of age who had detailed clinical information available; of these cases, 792 of 809 (98%) had elevated troponin levels, 569 of 794 (72%) had abnormal electrocardiogram results, and 223 of 312 (72%) had abnormal cardiac magnetic resonance imaging results. Julia W. Gargano, PhD1,*; Megan Wallace, DrPH1,*; Stephen C. Hadler, MD1; Gayle Langley, MD1; John R. Su, MD, PhD1; Matthew E. Oster, MD1; Karen R. Broder, MD1; Julianne Gee, MPH1; Eric Weintraub, MPH1; Tom Shimabukuro, MD1; Heather M. Scobie, PhD1; Danielle Moulia, MPH1; Lauri E. Markowitz, MD1; Melinda Wharton, MD1; Veronica V. McNally, JD2; Jos R. Romero, MD3; H. Keipp Talbot, MD4; Grace M. Lee, MD5; Matthew F. Daley, MD6; Sara E. Oliver, MD1 (View author affiliations). According to an analysis presented by a C.D.C. [Preprint]. Both Pfizer-BioNTech and Moderna vaccines are mRNA vaccines encoding the stabilized prefusion spike glycoprotein of SARS-CoV-2, the virus that causes COVID-19. mmwrq@cdc.gov. Myocarditis and pericarditis have rarely been reported. the date of publication. COVID-19 vaccines lower the risk of life-threatening heart problems and other serious health issues. 2023 Feb 13;11(2):432. doi: 10.3390/vaccines11020432. An analysis of almost 400 patients with myocarditis linked with COVID-19 illness found that about 15% died within 6 months.9. Importance: CDC twenty four seven. 1CDC COVID-19 Response Team; 2Franny Strong Foundation, West Bloomfield, Michigan; 3Arkansas Department of Health; 4Vanderbilt University School of Medicine, Nashville, Tennessee; 5Stanford University School of Medicine, Stanford, California; 6Institute for Health Research, Kaiser Permanente Colorado, Denver, Colorado. Currently, about 1,000 cases of myocarditis and pericarditis have been reported after vaccination against COVID-19 with one of the mRNA vaccines, Pfizer/BioNTech or Moderna. Reports of myocarditis and pericarditis after vaccination are rare. FLEG: The CDC (Centers for Disease Control and Prevention) recommends COVID-19 vaccination for children as young as 6 months. Law, Y. M., Lal, A. K., Chen, S., ihkov, D., Cooper, L. T., Jr, Deshpande, S., Godown, J., Grosse-Wortmann, L., Robinson, J. D., Towbin, J. Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website. We dont know exactly how often this happens, but one study estimated that myocarditis affects about 40 people out of every 1,000,000 people who test positive for COVID-19.3 However, myocarditis is much more common in patients hospitalized for COVID-19 (226 per 100,000).
CDC says there's likely link between rare heart inflammation in - CNBC In a comprehensive analysis of 1,626 myocarditis cases in the U.S. VAERS, Oster, et al., concluded the highest rates of VAM are concentrated in young males, as follows: 6 70.6 per million in males 12-15 years 105.9 per million in males 16-17 years 52.4 per million for Pfizer-BioNTech and 56.3 million for Moderna per million in males 18-24 years. There might be a 2.5 times higher . If you have concerns about COVID-19 vaccination, talk with your healthcare provider or your childs doctor, nurse, or clinic. The cases have been most common in male adolescents and young adults, occurring most often after the second dose, and usually within several days of receiving the vaccine. Researchers also looked at rates per million doses and the rate was 35.6 cases per million for Moderna and 12.6 per million for Pfizer-;an almost threefold increase after Moderna shots vs.. Incidence Rates and Rate Ratios of Myocarditis in Vaccinated Individuals Compared With Control Groups. Pillay J, Gaudet L, Wingert A, Bialy L, Mackie AS, Paterson DI, Hartling L. BMJ. In the past few weeks, anti-vaxxers have rallied behind a nonpeer-reviewed study by a group of Canadian researchers as evidence against COVID-19 vaccines. Views equals page views plus PDF downloads.
More Myocarditis After Moderna COVID Vax, But Rates Low Overall - Medscape Cookies used to make website functionality more relevant to you. endobj
Would you like email updates of new search results? Hromi-Jahjefendi A, Barh D, Uversky V, Aljabali AA, Tambuwala MM, Alzahrani KJ, Alzahrani FM, Alshammeri S, Lundstrom K. Vaccines (Basel).
COVID vaccine-related myocarditis rare, usually mild, studies say Patone, M., Mei, X. W., Handunnetthi, L., Dixon, S., Zaccardi, F., Shankar-Hari, M., Watkinson, P., Khunti, K., Harnden, A., Coupland, C., Channon, K. M., Mills, N. L., Sheikh, A., & Hippisley-Cox, J. Patients can usually return to their normal daily activities after their symptoms improve. The vaccines are very effective against severe COVID-19 and protect your heart from the serious health consequences of the disease. CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. ** The ACIP COVID-19 Vaccines Safety Technical (VaST) Work Group, comprising independent vaccine safety expert consultants, had also reviewed safety data on myocarditis after receipt of mRNA COVID-19 vaccines at its weekly meetings. Annie, F. H., Alkhaimy, H., Nanjundappa, A., & Elashery, A. Again, females had lower rates for both the first . FLEG: The bottom line is this: The benefits of getting vaccinated markedly outweigh the very small risk of vaccine-related myocarditis. Higher levels of vaccination coverage can reduce community transmission, which can protect against development and circulation of emerging variants.
PDF Updates on myocarditis and pericarditis following Moderna COVID -19 Diagnosis and Management of Myocarditis in Children: A Scientific Statement from the American Heart Association. You may have seen the recent reports linking rare cases. Myocarditis Cases After mRNA-Based COVID-19 Vaccination in the US. Jerome Fleg, M.D., a program officer with the National Heart, Lung, and Blood Institute (NHLBI) Division of Cardiovascular Sciences, oversees and conducts research on heart disease. Cookies used to make website functionality more relevant to you. Reports of myocarditis to VAERS were adjudicated and summarized for all age groups. The .gov means its official. On 9 July 2021, the COVID-19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety (GACVS) issued a statement regarding reports of myocarditis and pericarditis following COVID-19 mRNA vaccines (1).